United States Anticoagulants Market Size, Share, and Forecast 2025-2032: From US$38.13 Billion in 2024 to US$73.91 Billion at 8.6% CAGR, Driven by FDA Generic Rivaroxaban Approvals, Eliquis Discounts, and Pipeline Advances like VMX-C001

The Global Anticoagulants Market reached US$ 38.13 billion in 2024 and is expected to reach US$ 73.91 billion by 2032, growing at a CAGR of 8.6% during the forecast period 2025-2032.

According to DataM Intelligence has published a new research report on "Anticoagulants Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

📌 Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/anticoagulants-market?rk

➣ Recent Developments:

United States: Recent Industry Developments

✅ In March 2025, the U.S. FDA approved the first generic versions of rivaroxaban (Xarelto) 2.5 mg tablets, expanding access for patients with coronary artery disease and peripheral artery disease.

✅ In July 2025, Bristol Myers Squibb and Pfizer announced that, starting September 8, 2025, their blood thinner Eliquis will be available directly to cash-paying patients at a discounted rate through the Eliquis 360 Support program.

✅ In September 2025, CSL Limited partnered with Dutch biotech firm VarmX to develop VMX-C001, a drug aimed at managing severe bleeding in patients on anticoagulants, with a targeted 2029 commercial launch.

➣ Anticoagulant Pipeline Developments

✅ In September 2025, CSL Limited partnered with Dutch biotech firm VarmX to develop VMX-C001, a drug aimed at managing severe bleeding in patients on anticoagulants. The partnership includes an upfront payment of $117 million and potential total investments up to $388 million, with a targeted 2029 commercial launch.

✅ In August 2025, Cadrenal Therapeutics announced plans to initiate a clinical trial for tecarfarin in patients with end-stage kidney disease transitioning to dialysis. The trial aims to address critical treatment gaps in this population, with site activation and patient enrollment planned for later this year.

✅ In July 2025, Cadrenal Therapeutics enhanced its anticoagulation pipeline by acquiring eXIthera's portfolio of Factor XIa inhibitors, including frunexian, a first-in-class intravenous (IV) Factor XIa inhibitor developed for acute care settings.

➣ Top Industry Players:

Johnson & Johnson, Pfizer Inc., Bristol-Myers Squibb, DAIICHI SANKYO COMPANY, LIMITED., Boehringer Ingelheim International GmbH., Sanofi, Aspen Healthcare FZ LLC, Teva Pharmaceuticals USA, Inc., and Bayer AG.

📌 Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @: https://www.datamintelligence.com/buy-now-page?report=anticoagulants-market?rk

➣ Key Segments:

By Drug Class: Novel Oral Anticoagulants, Heparin and Low-Molecular-Weight Heparin, Vitamin K Antagonists, Others.

By Route of Administration: Oral Anticoagulants, Injectable Anticoagulants.

By Application: Atrial Fibrillation & Heart Attack, , Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Others.

By Distribution Channel: Hospitals, Academic & Research Institutes.

📌 Get Customization in the report as per your requirements: https://datamintelligence.com/customize/anticoagulants-market?rk

📌 Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/anticoagulants-market?rk

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

☛ Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?rk

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.